CD8A and glioma: The MEDIC schedule activated robust and persistent immune responses, as well as induced a striking and extended tumor regression.More effective than the corresponding daily low-dose metronomic regimen.Induction of a strong CD8+ T cell response leading to tumor disappearance and gain of immune memory in the GL261 glioma xenograft.